Safety and Efficacy of ombitasvir/paritaprevir/ritonavir with or without dasabuvir Plus ribavirin in hepatitis C virus genotype 1 or 4 infected patients with compensated cirrhosis : ABACUS compassionate-use nationwide Italian programme

Trial Profile

Safety and Efficacy of ombitasvir/paritaprevir/ritonavir with or without dasabuvir Plus ribavirin in hepatitis C virus genotype 1 or 4 infected patients with compensated cirrhosis : ABACUS compassionate-use nationwide Italian programme

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 May 2018

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 28 May 2018 Results (n=240) assessing safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years, were published in the Infection
    • 03 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top